| DB ID | MyCo_7090 |
| Title | Active screening of COVID-19-associated pulmonary aspergillosis with serum beta-glucan and endotracheal aspirates galactomannan and fungal culture |
| Year | 2022 |
| PMID | 36380646 |
| Fungal Diseases involved | Pulmonary aspergillosis |
| Associated Medical Condition | COVID-19 |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study was approved by the Area Vasta Emilia Nord ethics committee (protocol number 787/2021/OSS/AUSLRE). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Italy |
| Cohort | A total of 102 patients were screened (median age 64 years, range 39– |
| Cohort No. | 102 |
| Age Group | 39-79 |
| P Value | p=.0004 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | COVID-¬ 19-¬ associated pulmonary aspergillosis (CAPA) has been widely reported in the past two years by several authors and specific diagnostic criteria have been proposed in a Consensus by European Confederation of Medical Mycology/International Society for Human and Animal Mycology (ECMM/ISHAM) to better de-fine CAPA cases for clinical studies. The Consensus suggested to perform an active screening of CAPA in COVID-¬ intensive care unit (ICU), ideally performing three times per week serum galactomannan and once per week collection of respiratory samples for galactomannan and fungal culture, with any positivity triggering for CAPA in- vestigations. Furthermore, the authors suggested a ‘possible’ CAPA diagnosis using the non-¬ bronchoscopic alveolar lavage (NB-¬ BAL), in- creasing the galactomannan cut-¬ off of this sample to 4.5 optical density index (ODI). |
| Technique | Assay |
| Analysis Method | Wako BDG assay |
| ELISA kits | ELISA Kit- Platelia Aspergillus (Platelia Aspergillus EIA; Bio-Rad, Marnes la Coquette, France) |
| Assay Data | None |
| Validation Techniques used | Wako BDG assay, FDA Approved -Platelia Aspergillus Ag ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
